View ValuationWOLVES HAND 将来の成長Future 基準チェック /36WOLVES HANDは、12.4%と8.1%でそれぞれ年率12.4%で利益と収益が成長すると予測される一方、EPSはgrowで12.4%年率。主要情報12.4%収益成長率12.43%EPS成長率Healthcare 収益成長2.9%収益成長率8.1%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日24 Dec 2025今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to JP¥1,803, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 16x in the Healthcare industry in Japan. Total returns to shareholders of 190% over the past year.Reported Earnings • Feb 14Second quarter 2026 earnings released: EPS: JP¥17.97 (vs JP¥16.59 in 2Q 2025)Second quarter 2026 results: EPS: JP¥17.97 (up from JP¥16.59 in 2Q 2025). Revenue: JP¥1.43b (up 11% from 2Q 2025). Net income: JP¥135.0m (up 8.9% from 2Q 2025). Profit margin: 9.4% (in line with 2Q 2025). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Japan.お知らせ • Dec 27WOLVES HAND Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026WOLVES HAND Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026分析記事 • Dec 19Investors Should Be Encouraged By WOLVES HAND's (TSE:194A) Returns On CapitalTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...Valuation Update With 7 Day Price Move • Dec 11Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to JP¥1,667, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 15x in the Healthcare industry in Japan. Total returns to shareholders of 121% over the past year.Reported Earnings • Nov 16First quarter 2026 earnings released: EPS: JP¥22.06 (vs JP¥33.38 in 1Q 2025)First quarter 2026 results: EPS: JP¥22.06 (down from JP¥33.38 in 1Q 2025). Revenue: JP¥1.37b (down 7.0% from 1Q 2025). Net income: JP¥165.0m (down 34% from 1Q 2025). Profit margin: 12% (down from 17% in 1Q 2025). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Nov 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to JP¥1,594, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 13x in the Healthcare industry in Japan. Total returns to shareholders of 88% over the past year.分析記事 • Oct 28WOLVES HAND (TSE:194A) Has A Pretty Healthy Balance SheetSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Valuation Update With 7 Day Price Move • Oct 20Investor sentiment improves as stock rises 23%After last week's 23% share price gain to JP¥1,331, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 14x in the Healthcare industry in Japan. Total returns to shareholders of 53% over the past year.New Risk • Oct 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risks High level of debt (60% net debt to equity). Market cap is less than US$100m (JP¥8.11b market cap, or US$53.8m).分析記事 • Oct 03Investors Still Aren't Entirely Convinced By WOLVES HAND Co., Ltd.'s (TSE:194A) Earnings Despite 26% Price JumpDespite an already strong run, WOLVES HAND Co., Ltd. ( TSE:194A ) shares have been powering on, with a gain of 26% in...お知らせ • Sep 27WOLVES HAND Co., Ltd. to Report Q1, 2026 Results on Nov 14, 2025WOLVES HAND Co., Ltd. announced that they will report Q1, 2026 results on Nov 14, 2025Valuation Update With 7 Day Price Move • Sep 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥1,097, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 14x in the Healthcare industry in Japan. Total returns to shareholders of 1.0% over the past year.分析記事 • Aug 19Even With A 34% Surge, Cautious Investors Are Not Rewarding WOLVES HAND Co., Ltd.'s (TSE:194A) Performance CompletelyThe WOLVES HAND Co., Ltd. ( TSE:194A ) share price has done very well over the last month, posting an excellent gain of...お知らせ • Aug 15WOLVES HAND Co., Ltd., Annual General Meeting, Sep 26, 2025WOLVES HAND Co., Ltd., Annual General Meeting, Sep 26, 2025.お知らせ • Jun 24WOLVES HAND Co., Ltd. to Report Fiscal Year 2025 Results on Aug 15, 2025WOLVES HAND Co., Ltd. announced that they will report fiscal year 2025 results on Aug 15, 2025New Risk • Jun 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (89% net debt to equity). Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (JP¥5.34b market cap, or US$36.9m).お知らせ • Apr 23WOLVES HAND Co., Ltd. to Report Q3, 2025 Results on May 15, 2025WOLVES HAND Co., Ltd. announced that they will report Q3, 2025 results on May 15, 2025New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (98% net debt to equity). Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (JP¥4.72b market cap, or US$33.0m).Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to JP¥587, the stock trades at a trailing P/E ratio of 7.9x. Average trailing P/E is 12x in the Healthcare industry in Japan.お知らせ • Jan 24WOLVES HAND Co., Ltd. to Report Q2, 2025 Results on Feb 14, 2025WOLVES HAND Co., Ltd. announced that they will report Q2, 2025 results on Feb 14, 2025お知らせ • Jan 08WOLVES HAND Co., Ltd. (TSE:194A) completed the acquisition of Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda.WOLVES HAND Co., Ltd. (TSE:194A) acquired Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda on January 6, 2025. A cash consideration will be paid by WOLVES HAND Co., Ltd. As part of consideration, an undisclosed value is paid towards assets of Animal hospital business at Yasuda Animal Hospital. The expected completion of the transaction is January 6, 2025. WOLVES HAND Co., Ltd. (TSE:194A) completed the acquisition of Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda on January 6, 2025.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to JP¥980, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 16x in the Healthcare industry in Japan.Valuation Update With 7 Day Price Move • Sep 09Investor sentiment improves as stock rises 18%After last week's 18% share price gain to JP¥1,125, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 15x in the Healthcare industry in Japan.Reported Earnings • Aug 14Full year 2024 earnings released: EPS: JP¥75.15 (vs JP¥68.16 in FY 2023)Full year 2024 results: EPS: JP¥75.15 (up from JP¥68.16 in FY 2023). Revenue: JP¥4.99b (up 7.3% from FY 2023). Net income: JP¥558.0m (up 10% from FY 2023). Profit margin: 11% (in line with FY 2023).お知らせ • Aug 09WOLVES HAND Co., Ltd. (TSE:194A) agreed to acquire Soyokaze Co., Ltd.WOLVES HAND Co., Ltd. (TSE:194A) agreed to acquire Soyokaze Co., Ltd. on August 8, 2024. For the period ending August 31, 2023, Soyokaze Co., Ltd. reported total revenue of ¥290 million, EBIT of ¥29 million and net income of ¥22 million. As of August 31, 2023, Soyokaze Co., Ltd. reported total assets of ¥191 million and total common equity of ¥99 million.Valuation Update With 7 Day Price Move • Aug 03Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to JP¥783, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 15x in the Healthcare industry in Japan.Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improves as stock rises 19%After last week's 19% share price gain to JP¥1,149, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 17x in the Healthcare industry in Japan.Board Change • Jun 30High number of new directorsThere are 7 new directors who have joined the board in the last 3 years. Independent Outside Director Hiroshi Nakata was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 21WOLVES HAND Co., Ltd. has completed an IPO in the amount of ¥703.087 million.WOLVES HAND Co., Ltd. has completed an IPO in the amount of ¥703.087 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 686,400 Price\Range: ¥770 Discount Per Security: ¥61.6 Security Name: Common Stock Security Type: Common Stock Securities Offered: 176,700 Price\Range: ¥770 Discount Per Security: ¥61.6 Security Name: Common Stock Security Type: Common Stock Securities Offered: 50,000 Price\Range: ¥770 Discount Per Security: ¥61.6 Transaction Features: Sponsor Backed Offering業績と収益の成長予測TSE:194A - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20287,000980N/AN/A16/30/20276,500880N/AN/A16/30/20265,950780N/AN/A112/31/20255,7497168171,014N/A9/30/20255,577691N/AN/AN/A6/30/20255,463593833948N/A3/31/20255,270549N/AN/AN/A6/30/20244,990558412857N/A6/30/20234,651506N/AN/AN/A6/30/20224,295316N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 194Aの予測収益成長率 (年間12.4% ) は 貯蓄率 ( 0.8% ) を上回っています。収益対市場: 194Aの収益 ( 12.4% ) はJP市場 ( 10.2% ) よりも速いペースで成長すると予測されています。高成長収益: 194Aの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 194Aの収益 ( 8.1% ) JP市場 ( 6.1% ) よりも速いペースで成長すると予測されています。高い収益成長: 194Aの収益 ( 8.1% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 194Aの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/09 02:44終値2026/05/08 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋WOLVES HAND Co., Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Koichi HariyaIchiyoshi Research Institute Inc.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to JP¥1,803, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 16x in the Healthcare industry in Japan. Total returns to shareholders of 190% over the past year.
Reported Earnings • Feb 14Second quarter 2026 earnings released: EPS: JP¥17.97 (vs JP¥16.59 in 2Q 2025)Second quarter 2026 results: EPS: JP¥17.97 (up from JP¥16.59 in 2Q 2025). Revenue: JP¥1.43b (up 11% from 2Q 2025). Net income: JP¥135.0m (up 8.9% from 2Q 2025). Profit margin: 9.4% (in line with 2Q 2025). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Japan.
お知らせ • Dec 27WOLVES HAND Co., Ltd. to Report Q2, 2026 Results on Feb 13, 2026WOLVES HAND Co., Ltd. announced that they will report Q2, 2026 results on Feb 13, 2026
分析記事 • Dec 19Investors Should Be Encouraged By WOLVES HAND's (TSE:194A) Returns On CapitalTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...
Valuation Update With 7 Day Price Move • Dec 11Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to JP¥1,667, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 15x in the Healthcare industry in Japan. Total returns to shareholders of 121% over the past year.
Reported Earnings • Nov 16First quarter 2026 earnings released: EPS: JP¥22.06 (vs JP¥33.38 in 1Q 2025)First quarter 2026 results: EPS: JP¥22.06 (down from JP¥33.38 in 1Q 2025). Revenue: JP¥1.37b (down 7.0% from 1Q 2025). Net income: JP¥165.0m (down 34% from 1Q 2025). Profit margin: 12% (down from 17% in 1Q 2025). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Nov 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to JP¥1,594, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 13x in the Healthcare industry in Japan. Total returns to shareholders of 88% over the past year.
分析記事 • Oct 28WOLVES HAND (TSE:194A) Has A Pretty Healthy Balance SheetSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Valuation Update With 7 Day Price Move • Oct 20Investor sentiment improves as stock rises 23%After last week's 23% share price gain to JP¥1,331, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 14x in the Healthcare industry in Japan. Total returns to shareholders of 53% over the past year.
New Risk • Oct 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risks High level of debt (60% net debt to equity). Market cap is less than US$100m (JP¥8.11b market cap, or US$53.8m).
分析記事 • Oct 03Investors Still Aren't Entirely Convinced By WOLVES HAND Co., Ltd.'s (TSE:194A) Earnings Despite 26% Price JumpDespite an already strong run, WOLVES HAND Co., Ltd. ( TSE:194A ) shares have been powering on, with a gain of 26% in...
お知らせ • Sep 27WOLVES HAND Co., Ltd. to Report Q1, 2026 Results on Nov 14, 2025WOLVES HAND Co., Ltd. announced that they will report Q1, 2026 results on Nov 14, 2025
Valuation Update With 7 Day Price Move • Sep 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥1,097, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 14x in the Healthcare industry in Japan. Total returns to shareholders of 1.0% over the past year.
分析記事 • Aug 19Even With A 34% Surge, Cautious Investors Are Not Rewarding WOLVES HAND Co., Ltd.'s (TSE:194A) Performance CompletelyThe WOLVES HAND Co., Ltd. ( TSE:194A ) share price has done very well over the last month, posting an excellent gain of...
お知らせ • Aug 15WOLVES HAND Co., Ltd., Annual General Meeting, Sep 26, 2025WOLVES HAND Co., Ltd., Annual General Meeting, Sep 26, 2025.
お知らせ • Jun 24WOLVES HAND Co., Ltd. to Report Fiscal Year 2025 Results on Aug 15, 2025WOLVES HAND Co., Ltd. announced that they will report fiscal year 2025 results on Aug 15, 2025
New Risk • Jun 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (89% net debt to equity). Share price has been volatile over the past 3 months (7.2% average weekly change). Market cap is less than US$100m (JP¥5.34b market cap, or US$36.9m).
お知らせ • Apr 23WOLVES HAND Co., Ltd. to Report Q3, 2025 Results on May 15, 2025WOLVES HAND Co., Ltd. announced that they will report Q3, 2025 results on May 15, 2025
New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (98% net debt to equity). Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (JP¥4.72b market cap, or US$33.0m).
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to JP¥587, the stock trades at a trailing P/E ratio of 7.9x. Average trailing P/E is 12x in the Healthcare industry in Japan.
お知らせ • Jan 24WOLVES HAND Co., Ltd. to Report Q2, 2025 Results on Feb 14, 2025WOLVES HAND Co., Ltd. announced that they will report Q2, 2025 results on Feb 14, 2025
お知らせ • Jan 08WOLVES HAND Co., Ltd. (TSE:194A) completed the acquisition of Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda.WOLVES HAND Co., Ltd. (TSE:194A) acquired Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda on January 6, 2025. A cash consideration will be paid by WOLVES HAND Co., Ltd. As part of consideration, an undisclosed value is paid towards assets of Animal hospital business at Yasuda Animal Hospital. The expected completion of the transaction is January 6, 2025. WOLVES HAND Co., Ltd. (TSE:194A) completed the acquisition of Animal hospital business at Yasuda Animal Hospital from Kazuo Yasuda on January 6, 2025.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to JP¥980, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 16x in the Healthcare industry in Japan.
Valuation Update With 7 Day Price Move • Sep 09Investor sentiment improves as stock rises 18%After last week's 18% share price gain to JP¥1,125, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 15x in the Healthcare industry in Japan.
Reported Earnings • Aug 14Full year 2024 earnings released: EPS: JP¥75.15 (vs JP¥68.16 in FY 2023)Full year 2024 results: EPS: JP¥75.15 (up from JP¥68.16 in FY 2023). Revenue: JP¥4.99b (up 7.3% from FY 2023). Net income: JP¥558.0m (up 10% from FY 2023). Profit margin: 11% (in line with FY 2023).
お知らせ • Aug 09WOLVES HAND Co., Ltd. (TSE:194A) agreed to acquire Soyokaze Co., Ltd.WOLVES HAND Co., Ltd. (TSE:194A) agreed to acquire Soyokaze Co., Ltd. on August 8, 2024. For the period ending August 31, 2023, Soyokaze Co., Ltd. reported total revenue of ¥290 million, EBIT of ¥29 million and net income of ¥22 million. As of August 31, 2023, Soyokaze Co., Ltd. reported total assets of ¥191 million and total common equity of ¥99 million.
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to JP¥783, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 15x in the Healthcare industry in Japan.
Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improves as stock rises 19%After last week's 19% share price gain to JP¥1,149, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 17x in the Healthcare industry in Japan.
Board Change • Jun 30High number of new directorsThere are 7 new directors who have joined the board in the last 3 years. Independent Outside Director Hiroshi Nakata was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 21WOLVES HAND Co., Ltd. has completed an IPO in the amount of ¥703.087 million.WOLVES HAND Co., Ltd. has completed an IPO in the amount of ¥703.087 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 686,400 Price\Range: ¥770 Discount Per Security: ¥61.6 Security Name: Common Stock Security Type: Common Stock Securities Offered: 176,700 Price\Range: ¥770 Discount Per Security: ¥61.6 Security Name: Common Stock Security Type: Common Stock Securities Offered: 50,000 Price\Range: ¥770 Discount Per Security: ¥61.6 Transaction Features: Sponsor Backed Offering